Age-related macular degeneration (AMD) is a major cause of retinal damage, the leading cause of blindness in Western countries and, as the name implies, a disease of aging. Like other age-related diseases, AMD is particularly challenging to study because it takes decades to develop and so any research model must recapitulate the conditions of an older organism. Genome-wide association studies (GWASs) and linkage analyses have provided the first clues to what might cause AMD. These studies identified three single nucleotide polymorphisms (SNPs) that are strong risk factors for AMD.1 One SNP lies in the 402H allele in the CFH gene and the two others are tightly linked and lie in the neighboring HTRA1 and ARMS2 genes. These SNPs confer the most significant genetic risk factors in the history of GWAS studies in human genetics. People homozygous for these SNPs have a 50-fold increased risk of AMD. How these mutations might cause sight to deteriorate is unclear, however, because the underlying molecular mechanisms of AMD are unknown. Recently, however, our unbiased proteome analysis suggested super oxide dismutase (SOD) mechanisms are perturbed in affected cells and that, over time, this introduces reactive oxidative species (ROS) mediated cellular insults that eventually manifest as AMD. If ROS metabolism is indeed disrupted in AMD, then we might finally begin to address the causes of the disease. We believe the hurdles faced in finding causes and treatments for AMD could be circumvented by stem cell technologies. To this end we have found a way to differentiate stem cells from patients into retinal cells. Moreover, we developed a protocol that recapitulates aging in these patient-stem-cell-derived retinal cells. Finally, through gene-targeting technology, we can manipulate the stem cell genome, targeting disease- associated SNPs, to determine the individual contributions of each. By applying these powerful methodologies, we believe we can finally identify the root causes of AMD and so begin to develop new therapies. Our goals will be accomplished in two specific aims:
Aim 1 A. Use the CRISPR/Cas9 system to convert HTRA1 and ARMS2 alleles from low-risk to high risk in patient-derived stem cells.
Aim 1 B. Determine the individual contribution of human HTRA1 and ARMS2 alleles to AMD pathogenesis. Test whether CRISPR conversion from low to high-risk AMD alleles in Aim 1A affects ROS levels in cells.
Aim 2. Test the function of patient-stem-cell-derived RPE in a human-mouse chimera, in vivo assay.

Public Health Relevance

Age-related macular degeneration (AMD) is a major cause of retinal damage, the leading cause of blindness in Western countries and, as the name implies, a disease of aging. By applying stem cell and gene editing methodologies, we believe we can finally identify the root causes of AMD and so begin to develop new therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AG050437-02
Application #
9050619
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
St Hillaire-Clarke, Coryse
Project Start
2015-04-15
Project End
2017-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Iowa
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52246
Xu, Christine L; Park, Karen Sophia; Tsang, Stephen H (2018) CRISPR/Cas9 genome surgery for retinal diseases. Drug Discov Today Technol 28:23-32
Kroeger, Heike; Grimsey, Neil; Paxman, Ryan et al. (2018) The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Sci Signal 11:
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Machlab, Daniel A; Velez, Gabriel; Bassuk, Alexander G et al. (2018) ProSave: an application for restoring quantitative data to manipulated subsets of protein lists. Source Code Biol Med 13:3
Apatoff, Mary Ben L; Sengillo, Jesse D; White, Eugenia C et al. (2018) Autologous stem cell therapy for inherited and acquired retinal disease. Regen Med 13:89-96
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Velez, Gabriel; Tang, Peter H; Cabral, Thiago et al. (2018) Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease. Transl Vis Sci Technol 7:12
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative progression of retinitis pigmentosa by optical coherence tomography angiography. Sci Rep 8:13130
Liu, Katherine Y; Sengillo, Jesse D; Velez, Gabriel et al. (2018) Missense mutation in SLIT2 associated with congenital myopia, anisometropia, connective tissue abnormalities, and obesity. Orphanet J Rare Dis 13:138
DiCarlo, James E; Mahajan, Vinit B; Tsang, Stephen H (2018) Gene therapy and genome surgery in the retina. J Clin Invest 128:2177-2188

Showing the most recent 10 out of 62 publications